Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 154

1.

Assessment of Treatment With Sorafenib Plus Doxorubicin vs Sorafenib Alone in Patients With Advanced Hepatocellular Carcinoma: Phase 3 CALGB 80802 Randomized Clinical Trial.

Abou-Alfa GK, Shi Q, Knox JJ, Kaubisch A, Niedzwiecki D, Posey J, Tan BR Jr, Kavan P, Goel R, Lammers PE, Bekaii-Saab TS, Tam VC, Rajdev L, Kelley RK, El Dika I, Zemla T, Potaracke RI, Balletti J, El-Khoueiry AB, Harding JH, Suga JM, Schwartz LH, Goldberg RM, Bertagnolli MM, Meyerhardt J, O'Reilly EM, Venook AP.

JAMA Oncol. 2019 Sep 5. doi: 10.1001/jamaoncol.2019.2792. [Epub ahead of print]

PMID:
31486832
2.

Systemic therapy for gallbladder cancer.

Javle M, Zhao H, Abou-Alfa GK.

Chin Clin Oncol. 2019 Aug;8(4):44. doi: 10.21037/cco.2019.08.14.

3.

Second-line chemotherapy in advanced biliary cancers: A retrospective, multicenter analysis of outcomes.

Lowery MA, Goff LW, Keenan BP, Jordan E, Wang R, Bocobo AG, Chou JF, O'Reilly EM, Harding JJ, Kemeny N, Capanu M, Griffin AC, McGuire J, Venook AP, Abou-Alfa GK, Kelley RK.

Cancer. 2019 Aug 27. doi: 10.1002/cncr.32463. [Epub ahead of print]

PMID:
31454426
4.

Gallbladder cancer, a forgotten global cancer problem.

Abou-Alfa GK.

Chin Clin Oncol. 2019 Aug;8(4):30. doi: 10.21037/cco.2019.07.11. Epub 2019 Aug 5. No abstract available.

5.

Biliary tract cancer prognostic and predictive genomics.

Mondaca S, Nervi B, Pinto M, Abou-Alfa GK.

Chin Clin Oncol. 2019 Aug;8(4):42. doi: 10.21037/cco.2019.07.06. Epub 2019 Jul 29.

6.

Evaluation and management of incidental gallbladder cancer.

Zaidi MY, Abou-Alfa GK, Ethun CG, Shrikhande SV, Goel M, Nervi B, Primrose J, Valle JW, Maithel SK.

Chin Clin Oncol. 2019 Aug;8(4):37. doi: 10.21037/cco.2019.07.01. Epub 2019 Aug 5.

7.

Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma: a phase 1 study.

Lowery MA, Burris HA 3rd, Janku F, Shroff RT, Cleary JM, Azad NS, Goyal L, Maher EA, Gore L, Hollebecque A, Beeram M, Trent JC, Jiang L, Fan B, Aguado-Fraile E, Choe S, Wu B, Gliser C, Agresta SV, Pandya SS, Zhu AX, Abou-Alfa GK.

Lancet Gastroenterol Hepatol. 2019 Sep;4(9):711-720. doi: 10.1016/S2468-1253(19)30189-X. Epub 2019 Jul 9.

PMID:
31300360
8.

Immune checkpoint inhibitors for hepatocellular carcinoma.

El Dika I, Khalil DN, Abou-Alfa GK.

Cancer. 2019 Oct 1;125(19):3312-3319. doi: 10.1002/cncr.32076. Epub 2019 Jul 10. Review.

PMID:
31290997
9.

A Phase Ib/II Study of Ramucirumab in Combination with Emibetuzumab in Patients with Advanced Cancer.

Harding JJ, Zhu AX, Bauer TM, Choueiri TK, Drilon A, Voss MH, Fuchs CS, Abou-Alfa GK, Wijayawardana SR, Wang XA, Moser BA, Uruñuela A, Wacheck V, Bendell JC.

Clin Cancer Res. 2019 Sep 1;25(17):5202-5211. doi: 10.1158/1078-0432.CCR-18-4010. Epub 2019 May 29.

PMID:
31142504
10.

Maximizing response: a case report of salvage chemotherapy after immune checkpoint inhibition in a patient with previous chemo-refractory metastatic esophageal carcinoma.

Greally M, Agarwal R, El Dika I, Shamseddine A, El-Olayan A, Haibe Y, Paroder V, Shia J, Abou-Alfa GK, Ku GY.

J Gastrointest Oncol. 2019 Apr;10(2):367-372. doi: 10.21037/jgo.2018.10.07.

11.

Evolution of surgical management of gallbladder carcinoma and impact on outcome: results from two decades at a single-institution.

Creasy JM, Goldman DA, Gonen M, Dudeja V, O'Reilly EM, Abou-Alfa GK, Cercek A, Harding JJ, Balachandran VP, Drebin JA, Allen PJ, Kingham TP, D'Angelica MI, Jarnagin WR.

HPB (Oxford). 2019 Apr 23. pii: S1365-182X(19)30496-4. doi: 10.1016/j.hpb.2019.03.370. [Epub ahead of print]

PMID:
31027875
12.

Road map for fibrolamellar carcinoma: progress and goals of a diversified approach.

Kastenhuber ER, Craig J, Ramsey J, Sullivan KM, Sage J, de Oliveira S, Riehle KJ, Scott JD, Gordan JD, Bardeesy N, Abou-Alfa GK.

J Hepatocell Carcinoma. 2019 Jan 31;6:41-48. doi: 10.2147/JHC.S194764. eCollection 2019.

13.

The Use of Checkpoint Inhibitors in Patients With Hepatocellular Carcinoma.

Abou-Alfa GK.

Gastroenterol Hepatol (N Y). 2019 Jan;15(1):48-50. No abstract available.

14.

Biomarkers: What Role Do They Play (If Any) for Diagnosis, Prognosis and Tumor Response Prediction for Hepatocellular Carcinoma?

Harding JJ, Khalil DN, Abou-Alfa GK.

Dig Dis Sci. 2019 Apr;64(4):918-927. doi: 10.1007/s10620-019-05517-6. Review.

PMID:
30838478
15.

Ramucirumab and the controversial role of α-fetoprotein in hepatocellular carcinoma.

Abou-Alfa GK.

Lancet Oncol. 2019 Feb;20(2):177-179. doi: 10.1016/S1470-2045(19)30009-9. Epub 2019 Jan 18. No abstract available.

PMID:
30665868
16.

Systemic Therapy for Advanced Hepatocellular Carcinoma in an Evolving Landscape.

Mody K, Abou-Alfa GK.

Curr Treat Options Oncol. 2019 Jan 11;20(2):3. doi: 10.1007/s11864-019-0601-1. Review.

PMID:
30635732
17.

An Open-Label, Multicenter, Phase I, Dose Escalation Study with Phase II Expansion Cohort to Determine the Safety, Pharmacokinetics, and Preliminary Antitumor Activity of Intravenous TKM-080301 in Subjects with Advanced Hepatocellular Carcinoma.

El Dika I, Lim HY, Yong WP, Lin CC, Yoon JH, Modiano M, Freilich B, Choi HJ, Chao TY, Kelley RK, Brown J, Knox J, Ryoo BY, Yau T, Abou-Alfa GK.

Oncologist. 2019 Jun;24(6):747-e218. doi: 10.1634/theoncologist.2018-0838. Epub 2018 Dec 31.

18.

Binimetinib plus Gemcitabine and Cisplatin Phase I/II Trial in Patients with Advanced Biliary Cancers.

Lowery MA, Bradley M, Chou JF, Capanu M, Gerst S, Harding JJ, Dika IE, Berger M, Zehir A, Ptashkin R, Wong P, Rasalan-Ho T, Yu KH, Cercek A, Morgono E, Salehi E, Valentino E, Hollywood E, O'Reilly EM, Abou-Alfa GK.

Clin Cancer Res. 2019 Feb 1;25(3):937-945. doi: 10.1158/1078-0432.CCR-18-1927. Epub 2018 Dec 18.

PMID:
30563938
19.

Regional differences in gallbladder cancer pathogenesis: Insights from a multi-institutional comparison of tumor mutations.

Narayan RR, Creasy JM, Goldman DA, Gönen M, Kandoth C, Kundra R, Solit DB, Askan G, Klimstra DS, Basturk O, Allen PJ, Balachandran VP, D'Angelica MI, DeMatteo RP, Drebin JA, Kingham TP, Simpson AL, Abou-Alfa GK, Harding JJ, O'Reilly EM, Butte JM, Matsuyama R, Endo I, Jarnagin WR.

Cancer. 2019 Feb 15;125(4):575-585. doi: 10.1002/cncr.31850. Epub 2018 Nov 14.

PMID:
30427539
20.

Prospective Genotyping of Hepatocellular Carcinoma: Clinical Implications of Next-Generation Sequencing for Matching Patients to Targeted and Immune Therapies.

Harding JJ, Nandakumar S, Armenia J, Khalil DN, Albano M, Ly M, Shia J, Hechtman JF, Kundra R, El Dika I, Do RK, Sun Y, Kingham TP, D'Angelica MI, Berger MF, Hyman DM, Jarnagin W, Klimstra DS, Janjigian YY, Solit DB, Schultz N, Abou-Alfa GK.

Clin Cancer Res. 2019 Apr 1;25(7):2116-2126. doi: 10.1158/1078-0432.CCR-18-2293. Epub 2018 Oct 29.

PMID:
30373752
21.

Isoform Switching as a Mechanism of Acquired Resistance to Mutant Isocitrate Dehydrogenase Inhibition.

Harding JJ, Lowery MA, Shih AH, Schvartzman JM, Hou S, Famulare C, Patel M, Roshal M, Do RK, Zehir A, You D, Selcuklu SD, Viale A, Tallman MS, Hyman DM, Reznik E, Finley LWS, Papaemmanuil E, Tosolini A, Frattini MG, MacBeth KJ, Liu G, Fan B, Choe S, Wu B, Janjigian YY, Mellinghoff IK, Diaz LA, Levine RL, Abou-Alfa GK, Stein EM, Intlekofer AM.

Cancer Discov. 2018 Dec;8(12):1540-1547. doi: 10.1158/2159-8290.CD-18-0877. Epub 2018 Oct 24.

22.

A Phase Ib, Open-Label Study of Dalantercept, an Activin Receptor-Like Kinase 1 Ligand Trap, plus Sorafenib in Advanced Hepatocellular Carcinoma.

Abou-Alfa GK, Miksad RA, Tejani MA, Williamson S, Gutierrez ME, Olowokure OO, Sharma MR, El Dika I, Sherman ML, Pandya SS.

Oncologist. 2019 Feb;24(2):161-e70. doi: 10.1634/theoncologist.2018-0654. Epub 2018 Oct 23.

23.

Biomarker-Driven and Molecular Targeted Therapies for Hepatobiliary Cancers.

Harris WP, Wong KM, Saha S, Dika IE, Abou-Alfa GK.

Semin Oncol. 2018 Jun;45(3):116-123. doi: 10.1053/j.seminoncol.2018.03.002. Epub 2018 Mar 16. Review.

PMID:
30348531
24.

Cabozantinib in Hepatocellular Carcinoma.

Abou-Alfa GK, Borgman-Hagey AE, Kelley RK.

N Engl J Med. 2018 Oct 4;379(14):1384-1385. doi: 10.1056/NEJMc1810178. No abstract available.

PMID:
30281991
25.

Somatic HNF1A mutations in the malignant transformation of hepatocellular adenomas: a retrospective analysis of data from MSK-IMPACT and TCGA.

Hechtman JF, Abou-Alfa GK, Stadler ZK, Mandelker DL, Roehrl MHA, Zehir A, Vakiani E, Middha S, Klimstra DS, Shia J.

Hum Pathol. 2019 Jan;83:1-6. doi: 10.1016/j.humpath.2018.08.004. Epub 2018 Aug 17.

PMID:
30121369
26.

Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma.

Abou-Alfa GK, Meyer T, Cheng AL, El-Khoueiry AB, Rimassa L, Ryoo BY, Cicin I, Merle P, Chen Y, Park JW, Blanc JF, Bolondi L, Klümpen HJ, Chan SL, Zagonel V, Pressiani T, Ryu MH, Venook AP, Hessel C, Borgman-Hagey AE, Schwab G, Kelley RK.

N Engl J Med. 2018 Jul 5;379(1):54-63. doi: 10.1056/NEJMoa1717002.

27.

A phase 1 study of ADI-PEG 20 and modified FOLFOX6 in patients with advanced hepatocellular carcinoma and other gastrointestinal malignancies.

Harding JJ, Do RK, Dika IE, Hollywood E, Uhlitskykh K, Valentino E, Wan P, Hamilton C, Feng X, Johnston A, Bomalaski J, Li CF, O'Reilly EM, Abou-Alfa GK.

Cancer Chemother Pharmacol. 2018 Sep;82(3):429-440. doi: 10.1007/s00280-018-3635-3. Epub 2018 Jul 3.

PMID:
29971467
28.

Comprehensive Molecular Profiling of Intrahepatic and Extrahepatic Cholangiocarcinomas: Potential Targets for Intervention.

Lowery MA, Ptashkin R, Jordan E, Berger MF, Zehir A, Capanu M, Kemeny NE, O'Reilly EM, El-Dika I, Jarnagin WR, Harding JJ, D'Angelica MI, Cercek A, Hechtman JF, Solit DB, Schultz N, Hyman DM, Klimstra DS, Saltz LB, Abou-Alfa GK.

Clin Cancer Res. 2018 Sep 1;24(17):4154-4161. doi: 10.1158/1078-0432.CCR-18-0078. Epub 2018 May 30.

29.

Phase III randomized study of second line ADI-PEG 20 plus best supportive care versus placebo plus best supportive care in patients with advanced hepatocellular carcinoma.

Abou-Alfa GK, Qin S, Ryoo BY, Lu SN, Yen CJ, Feng YH, Lim HY, Izzo F, Colombo M, Sarker D, Bolondi L, Vaccaro G, Harris WP, Chen Z, Hubner RA, Meyer T, Sun W, Harding JJ, Hollywood EM, Ma J, Wan PJ, Ly M, Bomalaski J, Johnston A, Lin CC, Chao Y, Chen LT.

Ann Oncol. 2018 Jun 1;29(6):1402-1408. doi: 10.1093/annonc/mdy101.

PMID:
29659672
30.

I-124 codrituzumab imaging and biodistribution in patients with hepatocellular carcinoma.

Carrasquillo JA, O'Donoghue JA, Beylergil V, Ruan S, Pandit-Taskar N, Larson SM, Smith-Jones PM, Lyashchenko SK, Ohishi N, Ohtomo T, Abou-Alfa GK.

EJNMMI Res. 2018 Mar 5;8(1):20. doi: 10.1186/s13550-018-0374-8.

31.

Prospective Evaluation of Germline Alterations in Patients With Exocrine Pancreatic Neoplasms.

Lowery MA, Wong W, Jordan EJ, Lee JW, Kemel Y, Vijai J, Mandelker D, Zehir A, Capanu M, Salo-Mullen E, Arnold AG, Yu KH, Varghese AM, Kelsen DP, Brenner R, Kaufmann E, Ravichandran V, Mukherjee S, Berger MF, Hyman DM, Klimstra DS, Abou-Alfa GK, Tjan C, Covington C, Maynard H, Allen PJ, Askan G, Leach SD, Iacobuzio-Donahue CA, Robson ME, Offit K, Stadler ZK, O'Reilly EM.

J Natl Cancer Inst. 2018 Oct 1;110(10):1067-1074. doi: 10.1093/jnci/djy024.

32.

Brain Metastases in Pancreatic Ductal Adenocarcinoma: Assessment of Molecular Genotype-Phenotype Features-An Entity With an Increasing Incidence?

Jordan EJ, Lowery MA, Basturk O, Allen PJ, Yu KH, Tabar V, Beal K, Reidy DL, Yamada Y, Janjigian Y, Abou-Alfa GK, O'Reilly EM.

Clin Colorectal Cancer. 2018 Jun;17(2):e315-e321. doi: 10.1016/j.clcc.2018.01.009. Epub 2018 Feb 7.

PMID:
29496399
33.

Time-to-event modelling of effect of codrituzumab on overall survival in patients with hepatocellular carcinoma.

Nakamura M, Xu C, Diack C, Ohishi N, Lee RM, Iida S, Kawanishi T, Ohtomo T, Abou-Alfa GK, Chen YC.

Br J Clin Pharmacol. 2018 May;84(5):944-951. doi: 10.1111/bcp.13530. Epub 2018 Mar 9.

34.

Frequency, Morbidity, and Mortality of Bone Metastases in Advanced Hepatocellular Carcinoma.

Harding JJ, Abu-Zeinah G, Chou JF, Owen DH, Ly M, Lowery MA, Capanu M, Do R, Kemeny NE, O'Reilly EM, Saltz LB, Abou-Alfa GK.

J Natl Compr Canc Netw. 2018 Jan;16(1):50-58. doi: 10.6004/jnccn.2017.7024.

PMID:
29295881
35.

Case report: primary acinar cell carcinoma of the liver treated with multimodality therapy.

Jordan EJ, Basturk O, Shia J, Klimstra DS, Alago W, D'Angelica MI, Abou-Alfa GK, O'Reilly EM, Lowery MA.

J Gastrointest Oncol. 2017 Oct;8(5):E65-E72. doi: 10.21037/jgo.2017.06.21.

36.

Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma.

Javle M, Lowery M, Shroff RT, Weiss KH, Springfeld C, Borad MJ, Ramanathan RK, Goyal L, Sadeghi S, Macarulla T, El-Khoueiry A, Kelley RK, Borbath I, Choo SP, Oh DY, Philip PA, Chen LT, Reungwetwattana T, Van Cutsem E, Yeh KH, Ciombor K, Finn RS, Patel A, Sen S, Porter D, Isaacs R, Zhu AX, Abou-Alfa GK, Bekaii-Saab T.

J Clin Oncol. 2018 Jan 20;36(3):276-282. doi: 10.1200/JCO.2017.75.5009. Epub 2017 Nov 28.

37.

Treatment options after sorafenib failure in patients with hepatocellular carcinoma.

Dika IE, Abou-Alfa GK.

Clin Mol Hepatol. 2017 Dec;23(4):273-279. doi: 10.3350/cmh.2017.0108. Epub 2017 Nov 20. Review.

38.

A phase 1/1B trial of ADI-PEG 20 plus nab-paclitaxel and gemcitabine in patients with advanced pancreatic adenocarcinoma.

Lowery MA, Yu KH, Kelsen DP, Harding JJ, Bomalaski JS, Glassman DC, Covington CM, Brenner R, Hollywood E, Barba A, Johnston A, Liu KC, Feng X, Capanu M, Abou-Alfa GK, O'Reilly EM.

Cancer. 2017 Dec 1;123(23):4556-4565. doi: 10.1002/cncr.30897. Epub 2017 Aug 18.

39.

Real-Time Genomic Profiling of Pancreatic Ductal Adenocarcinoma: Potential Actionability and Correlation with Clinical Phenotype.

Lowery MA, Jordan EJ, Basturk O, Ptashkin RN, Zehir A, Berger MF, Leach T, Herbst B, Askan G, Maynard H, Glassman D, Covington C, Schultz N, Abou-Alfa GK, Harding JJ, Klimstra DS, Hechtman JF, Hyman DM, Allen PJ, Jarnagin WR, Balachandran VP, Varghese AM, Schattner MA, Yu KH, Saltz LB, Solit DB, Iacobuzio-Donahue CA, Leach SD, O'Reilly EM.

Clin Cancer Res. 2017 Oct 15;23(20):6094-6100. doi: 10.1158/1078-0432.CCR-17-0899. Epub 2017 Jul 28.

40.

An elderly man with remote history of metastatic melanoma now with localized pancreas cancer and new liver masses.

Vasan N, Braghiroli MI, Shoushtari AN, Do RKG, Edelweiss M, Shamseddine A, Faraj W, Mukherji D, Haydar A, Olayan A, Sabatin F, Assi R, El Dika I, Saltz LB, Abou-Alfa GK, O'Reilly EM.

J Gastrointest Oncol. 2017 Jun;8(3):596-602. doi: 10.21037/jgo.2017.01.21. No abstract available.

41.

Phase II Study of First-Line Trebananib Plus Sorafenib in Patients with Advanced Hepatocellular Carcinoma.

Abou-Alfa GK, Blanc JF, Miles S, Ganten T, Trojan J, Cebon J, Liem AK, Lipton L, Gupta C, Wu B, Bass M, Hollywood E, Ma J, Bradley M, Litten J, Saltz LB.

Oncologist. 2017 Jul;22(7):780-e65. doi: 10.1634/theoncologist.2017-0058. Epub 2017 Jun 7.

42.

Pharmacokinetics and safety of vismodegib in patients with advanced solid malignancies and hepatic impairment.

Abou-Alfa GK, Lewis LD, LoRusso P, Maitland M, Chandra P, Cheeti S, Colburn D, Williams S, Simmons B, Graham RA.

Cancer Chemother Pharmacol. 2017 Jul;80(1):29-36. doi: 10.1007/s00280-017-3315-8. Epub 2017 May 18.

43.

Proportion of cancer in a Middle eastern country attributable to established risk factors.

Charafeddine MA, Olson SH, Mukherji D, Temraz SN, Abou-Alfa GK, Shamseddine AI.

BMC Cancer. 2017 May 18;17(1):337. doi: 10.1186/s12885-017-3304-7.

44.

The role (if any) of chemotherapy in hepatocellular carcinoma.

El Dika I, Abou-Alfa GK.

Lancet Gastroenterol Hepatol. 2017 Jun;2(6):387-389. doi: 10.1016/S2468-1253(17)30104-8. Epub 2017 Apr 6. No abstract available.

PMID:
28497748
45.

Phase Ib study of codrituzumab in combination with sorafenib in patients with non-curable advanced hepatocellular carcinoma (HCC).

Abou-Alfa GK, Yen CJ, Hsu CH, O'Donoghue J, Beylergil V, Ruan S, Pandit-Taskar N, Gansukh B, Lyashchenko SK, Ma J, Wan P, Shao YY, Lin ZZ, Frenette C, O'Neil B, Schwartz L, Smith-Jones PM, Ohtomo T, Tanaka T, Morikawa H, Maki Y, Ohishi N, Chen YC, Agajanov T, Boisserie F, Di Laurenzio L, Lee R, Larson SM, Cheng AL, Carrasquilo JA.

Cancer Chemother Pharmacol. 2017 Feb;79(2):421-429. doi: 10.1007/s00280-017-3241-9. Epub 2017 Jan 24.

46.

Advances in cholangiocarcinoma research: report from the third Cholangiocarcinoma Foundation Annual Conference.

Abou-Alfa GK, Andersen JB, Chapman W, Choti M, Forbes SJ, Gores GJ, Hong TS, Harding JJ, Vander Heiden MG, Javle M, Kelley RK, Kwong LN, Lowery M, Merrell A, Miyabe K, Rhim A, Saha S, Sia D, Tanasanvimon S, Venook A, Valle JW, Walesky C, Whetstine J, Willenbring H, Zhu AX, Mayer D, Stanger BZ.

J Gastrointest Oncol. 2016 Dec;7(6):819-827. doi: 10.21037/jgo.2016.11.11. No abstract available.

47.

Reply to A. Braillon, M. Boulin et al, and J.-H. Zhong et al.

Brown KT, Do R, Gönen M, Covey AM, Getrajdman GI, Sofocleous CT, Jarnagin WR, D'Angelica MI, Allen PJ, Erinjeri JP, Brody LA, O'Neill GP, Johnson K, Garcia AR, Beattie CM, Zhao B, Solomon SB, Schwartz LH, DeMatteo RP, Abou-Alfa GK.

J Clin Oncol. 2017 Jan 10;35(2):258-259. Epub 2016 Oct 23. No abstract available.

PMID:
28056199
48.

Hepatocellular Carcinoma: Therapeutic Guidelines and Medical Treatment.

Kudo M, Trevisani F, Abou-Alfa GK, Rimassa L.

Liver Cancer. 2016 Nov;6(1):16-26. Epub 2016 Nov 29. Review.

49.

Interview with Dr Ghassan K Abou-Alfa.

Abou-Alfa GK.

Immunotherapy. 2016 Nov;8(11):1277-1279.

PMID:
27993088
50.

Combined intrahepatic cholangiocarcinoma and hepatocellular carcinoma.

Connell LC, Harding JJ, Shia J, Abou-Alfa GK.

Chin Clin Oncol. 2016 Oct;5(5):66. doi: 10.21037/cco.2016.10.02. Review.

Supplemental Content

Loading ...
Support Center